169 related articles for article (PubMed ID: 38181784)
21. The Red Blood Cell-Inflammation Vicious Circle in Sickle Cell Disease.
Nader E; Romana M; Connes P
Front Immunol; 2020; 11():454. PubMed ID: 32231672
[TBL] [Abstract][Full Text] [Related]
22. Alternative donor: αß/CD19 T-cell-depleted haploidentical hematopoietic stem cell transplantation for sickle cell disease.
Foell J; Kleinschmidt K; Jakob M; Troeger A; Corbacioglu S
Hematol Oncol Stem Cell Ther; 2020 Jun; 13(2):98-105. PubMed ID: 32202248
[TBL] [Abstract][Full Text] [Related]
23. Thrombospondin-1, Platelet Factor 4, and Galectin-1 Are Associated with Engraftment in Patients with Sickle Cell Disease who Underwent Haploidentical Hematopoietic Stem Cell Transplantation.
Shaikh A; Olkhanud PB; Gangaplara A; Kone A; Patel S; Gucek M; Fitzhugh CD
Transplant Cell Ther; 2022 May; 28(5):249.e1-249.e13. PubMed ID: 35131485
[TBL] [Abstract][Full Text] [Related]
24. Etavopivat, a Pyruvate Kinase Activator in Red Blood Cells, for the Treatment of Sickle Cell Disease.
Schroeder P; Fulzele K; Forsyth S; Ribadeneira MD; Guichard S; Wilker E; Marshall CG; Drake A; Fessler R; Konstantinidis DG; Seu KG; Kalfa TA
J Pharmacol Exp Ther; 2022 Mar; 380(3):210-219. PubMed ID: 35031585
[TBL] [Abstract][Full Text] [Related]
25. Hematopoietic stem cell transplantation for sickle cell disease: state of the science.
Talano JA; Cairo MS
Eur J Haematol; 2015 May; 94(5):391-9. PubMed ID: 25200500
[TBL] [Abstract][Full Text] [Related]
26. Hematopoietic stem cell transplantation for sickle cell disease: current practice and emerging trends.
Shenoy S
Hematology Am Soc Hematol Educ Program; 2011; 2011():273-9. PubMed ID: 22160045
[TBL] [Abstract][Full Text] [Related]
27. Characterization of reemergent anti-B red blood cell antibodies in a patient with recurrent acute myeloid leukemia with ABO-incompatible allogeneic peripheral blood stem cell transplantation.
Tajima K; Takizawa K; Yasuda T; Tsumanuma R; Okuyama S; Kumagai H; Omoto E; Okumura W
Transfusion; 2019 Nov; 59(11):3319-3323. PubMed ID: 31503348
[TBL] [Abstract][Full Text] [Related]
28. Correction of murine sickle cell disease by allogeneic haematopoietic cell transplantation with anti-3rd party veto cells.
Singh AK; Schetzen E; Yadav SK; Lustig EB; Liu WH; Yadav RK; Gale RP; McGinnis K; Reisner Y
Bone Marrow Transplant; 2021 Aug; 56(8):1818-1827. PubMed ID: 33658643
[TBL] [Abstract][Full Text] [Related]
29. Stage-dependent fate of Plasmodium falciparum-infected red blood cells in the spleen and sickle-cell trait-related protection against malaria.
Diakité SA; Ndour PA; Brousse V; Gay F; Roussel C; Biligui S; Dussiot M; Prendki V; Lopera-Mesa TM; Traoré K; Konaté D; Doumbia S; Cros J; Dokmak S; Fairhurst RM; Diakité M; Buffet PA
Malar J; 2016 Sep; 15(1):482. PubMed ID: 27655345
[TBL] [Abstract][Full Text] [Related]
30. Curative Therapies for Sickle Cell Disease.
Khemani K; Katoch D; Krishnamurti L
Ochsner J; 2019; 19(2):131-137. PubMed ID: 31258425
[No Abstract] [Full Text] [Related]
31. A cure for murine sickle cell disease through stable mixed chimerism and tolerance induction after nonmyeloablative conditioning and major histocompatibility complex-mismatched bone marrow transplantation.
Kean LS; Durham MM; Adams AB; Hsu LL; Perry JR; Dillehay D; Pearson TC; Waller EK; Larsen CP; Archer DR
Blood; 2002 Mar; 99(5):1840-9. PubMed ID: 11861303
[TBL] [Abstract][Full Text] [Related]
32. Is There Any Improvement of the Coagulation Imbalance in Sickle Cell Disease after Hematopoietic Stem Cell Transplantation?
Rozen L; Noubouossie DF; Dedeken L; Lê PQ; Ferster A; Demulder A
J Clin Med; 2019 Oct; 8(11):. PubMed ID: 31717804
[TBL] [Abstract][Full Text] [Related]
33. Highly Defined Induced Pluripotent Stem Cell Lines Mimic Donor Red Blood Cell Antigen Profiles for Therapeutic and Diagnostic Use.
Catelli LF; Mendes da Costa PN; Rós FA; Rodrigues ES; Ursoli FF; Santos FLS; Dorigan M; de Castilho LM; Covas DT; Kashima S
Cell Reprogram; 2024 Jun; 26(3):107-115. PubMed ID: 38917437
[TBL] [Abstract][Full Text] [Related]
34. Hematopoietic stem cell transplant referral patterns for children with sickle cell disease vary among pediatric hematologist/oncologists' practice focus: A Sickle Cell Transplant Advocacy and Research Alliance (STAR) study.
Meier ER; Abraham AA; Ngwube A; Janson IA; Guilcher GMT; Horan J; Kasow KA
Pediatr Blood Cancer; 2021 Mar; 68(3):e28861. PubMed ID: 33405370
[TBL] [Abstract][Full Text] [Related]
35. Granulocyte Colony-Stimulating Factor Is Safe and Well Tolerated following Allogeneic Transplantation in Patients with Sickle Cell Disease.
Shah NC; Bhoopatiraju S; Abraham A; Anderson E; Andreansky M; Bhatia M; Chaudhury S; Cuvelier GDE; Godder K; Grimley M; Hale G; Kamani N; Jacobsohn D; Ngwube A; Gilman AL; Skiles J; Yu LC; Shenoy S
Transplant Cell Ther; 2022 Mar; 28(3):174.e1-174.e5. PubMed ID: 34958973
[TBL] [Abstract][Full Text] [Related]
36. Evidence of benefits from using fresh and cryopreserved blood to transfuse patients with acute sickle cell disease.
Chadebech P; de Ménorval MA; Bodivit G; Mekontso-Dessap A; Pakdaman S; Jouard A; Galactéros F; Bierling P; Habibi A; Pirenne F
Transfusion; 2016 Jul; 56(7):1730-8. PubMed ID: 27184475
[TBL] [Abstract][Full Text] [Related]
37. Low Rates of Cerebral Infarction after Hematopoietic Stem Cell Transplantation in Patients with Sickle Cell Disease at High Risk for Stroke.
Carpenter JL; Nickel RS; Webb J; Khademian Z; Speller-Brown B; Majumdar S; Darbari DS; Campbell A; Zhang A; Abraham A
Transplant Cell Ther; 2021 Dec; 27(12):1018.e1-1018.e9. PubMed ID: 34530179
[TBL] [Abstract][Full Text] [Related]
38. Hematopoietic stem cells: potential new applications for translational medicine.
Felfly H; Haddad GG
J Stem Cells; 2014; 9(3):163-97. PubMed ID: 25157450
[TBL] [Abstract][Full Text] [Related]
39. Extensive multilineage analysis in patients with mixed chimerism after allogeneic transplantation for sickle cell disease: insight into hematopoiesis and engraftment thresholds for gene therapy.
Magnani A; Pondarré C; Bouazza N; Magalon J; Miccio A; Six E; Roudaut C; Arnaud C; Kamdem A; Touzot F; Gabrion A; Magrin E; Couzin C; Fusaro M; André I; Vernant JP; Gluckman E; Bernaudin F; Bories D; Cavazzana M
Haematologica; 2020 May; 105(5):1240-1247. PubMed ID: 31537695
[TBL] [Abstract][Full Text] [Related]
40. Whole blood viscosity and red blood cell adhesion: Potential biomarkers for targeted and curative therapies in sickle cell disease.
Kucukal E; Man Y; Hill A; Liu S; Bode A; An R; Kadambi J; Little JA; Gurkan UA
Am J Hematol; 2020 Nov; 95(11):1246-1256. PubMed ID: 32656816
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
